Published in Expert Rev Hematol on April 01, 2012
Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2012) 2.69
Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol (2014) 1.24
Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol (2012) 1.12
Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract (2015) 0.90
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. J Blood Med (2013) 0.89
ICON: Eosinophil Disorders. World Allergy Organ J (2012) 0.88
Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. Med Oncol (2013) 0.85
Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget (2015) 0.82
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Exp Hematol (2014) 0.81
Hypereosinophilia and seroconversion of rheumatoid arthritis. Clin Rheumatol (2014) 0.79
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget (2014) 0.76
Selective IgA deficiency mimicking Churg-Strauss syndrome and hypereosinophilic syndrome: a case report. Nagoya J Med Sci (2013) 0.76
[Eosinophilic pneumonia revealing B-cell non-Hodgkin lymphoma]. Pan Afr Med J (2016) 0.75
TRIP11-PDGFRB fusion in a patient with a therapy-related myeloid neoplasm with t(5;14)(q33;q32) after treatment for acute promyelocytic leukemia. Mol Cytogenet (2014) 0.75
Eosinophilia in Hematologic Disorders. Immunol Allergy Clin North Am (2015) 0.75
Circulating Human Eosinophils Share a Similar Transcriptional Profile in Asthma and Other Hypereosinophilic Disorders. PLoS One (2015) 0.75
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. Mediators Inflamm (2015) 0.75
Comparison of eosinophil density in staging bone marrow biopsies from Malawi and the United States. Pathol Int (2015) 0.75
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) (1975) 9.01
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia (2007) 8.34
Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med (1999) 6.04
Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med (2008) 5.94
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 4.93
The idiopathic hypereosinophilic syndrome. Blood (1994) 4.65
Eosinophils: biological properties and role in health and disease. Clin Exp Allergy (2008) 3.92
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
The hypereosinophilic syndromes. Ann Intern Med (1968) 3.60
Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol (2000) 3.27
RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med (1992) 3.25
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood (2002) 2.34
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol (2003) 2.31
Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med (1994) 2.29
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A (1988) 2.22
Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am (2007) 2.17
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 2.14
Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol (2010) 2.04
Eosinophilic disorders. J Allergy Clin Immunol (2007) 2.00
Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet (1987) 1.98
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol (2008) 1.90
Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood (2003) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol (2004) 1.84
Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol (2002) 1.82
Eosinophilia: secondary, clonal and idiopathic. Br J Haematol (2006) 1.82
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A (2004) 1.81
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol (2008) 1.79
Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol (2011) 1.76
Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol (2003) 1.72
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med (1996) 1.71
Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol (1988) 1.68
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia (2008) 1.65
The biology of the eosinophilic leukocyte. Annu Rev Med (1993) 1.65
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol (1989) 1.64
Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol (1987) 1.62
Eosinophil infiltration and degranulation in normal human tissue. Anat Rec (1998) 1.59
Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol (1992) 1.58
Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am (2007) 1.57
Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy (2009) 1.56
Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy (1992) 1.56
Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med (2009) 1.54
Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Clin Exp Allergy (2009) 1.51
Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils. Clin Exp Allergy (2002) 1.47
Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol (2000) 1.46
Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev (2011) 1.45
Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol (2000) 1.44
Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol (1995) 1.42
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood (2007) 1.40
GM-CSF, IL-3 and IL-5: cross-competition on human haemopoietic cells. Immunol Today (1992) 1.40
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. J Immunol (1992) 1.38
Episodic angioedema associated with eosinophilia. N Engl J Med (1984) 1.38
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia (2009) 1.37
Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am (2007) 1.37
Interleukin-3 is a differentiation factor for human basophils. Blood (1989) 1.34
The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res (2004) 1.33
What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol (2010) 1.33
Fc gamma and CD11/CD18 receptor expression on normal density and low density human eosinophils. Immunology (1990) 1.32
Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med (2003) 1.29
Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood (1985) 1.27
Hypereosinophilic syndrome: an update. Am J Hematol (2005) 1.27
Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol (2011) 1.25
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 1.25
The hypereosinophilic syndrome revisited. Annu Rev Med (2001) 1.25
Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev (2009) 1.22
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia (2004) 1.21
Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol (1997) 1.18
Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am (2007) 1.17
Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. J Biol Chem (1991) 1.17
Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol (1997) 1.17
Cytokine generation by eosinophils. J Allergy Clin Immunol (1994) 1.16
Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells. Blood (1984) 1.15
The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol (1994) 1.14
Eosinophils: structure and functions. Curr Opin Immunol (1994) 1.14
Making eosinophils through subtle shifts in transcription factor expression. J Exp Med (2002) 1.13
Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis x. J Pharmacol Exp Ther (2009) 1.12
The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol (1994) 1.12
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med (2008) 1.10
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica (2011) 1.10
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood (2006) 1.10
Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev (2001) 1.10
Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol (2008) 1.10
Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int (2005) 1.08
How I treat hypereosinophilic syndromes. Blood (2009) 1.07
alphadbeta2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J Exp Med (1998) 1.06
Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood (1992) 1.06
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol (2006) 9.36
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 6.05
Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med (2008) 5.94
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology (2003) 5.36
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 4.93
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology (2013) 4.20
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood (2005) 3.90
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood (2009) 3.69
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med (2013) 3.57
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood (2010) 3.41
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol (2011) 3.34
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet (2009) 3.21
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood (2007) 3.15
Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol (2005) 3.13
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med (2005) 3.06
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A (2002) 3.05
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A (2006) 2.94
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology (2010) 2.76
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol (2009) 2.71
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol (2011) 2.70
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet (2012) 2.64
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood (2009) 2.51
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol (2007) 2.44
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood (2009) 2.41
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol (2010) 2.29